CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
roughly in thirds (Casgevy, Phase 1 assets like CTX310/CTX320/CTX611, and deeper pipeline) and prioritizing new franchises in cardiovascular and autoimmune disease with data expected from six programs beyond Casgevy by mid-2027. CTX310 in vivo data: Early in vivo results showed near-saturating hepatocyte editing with ~80% ANGPTL3 reduction and biomarker effects of ~50% LDL and ~60% triglyceride drops, and management is engaging regulators to define the registrational path across multiple lipid disorder populations. Casgevy commercial update: Management called 2024–25 foundational with "well over $100 million" in 2025 sales, patient initiations rising from ~100 to 300+, cell collections beginning to inflect, and 2025 expected as the peak spend year for the franchise while profitability timing remains with partner Vertex. Interested in CRISPR Therapeutics AG? Here are five stocks we like better. CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows CRISPR Therapeutic
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $110.00 price target on the stock, up from $105.00.MarketBeat
- A Look At CRISPR Therapeutics (CRSP) Valuation After Upsized US$550 Million Convertible Note Offering [Yahoo! Finance]Yahoo! Finance
- Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- CRSP's page on the SEC website